12:00 AM
Aug 13, 2012
 |  BC Week In Review  |  Company News  |  Other News

Infinity cancer news

Infinity disclosed in its 2Q12 earnings that it reduced headcount by about 20% to 160. At Feb. 29, Infinity had 190 employees. The company said the cuts ranged across all areas of operations and were made with the intent to maintain all functions. The move comes after Infinity discontinued development of cancer compound saridegib and terminated a 2008 deal with Purdue Pharma L.P....

Read the full 301 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >